These findings have immediate translational implications for repurposing FDA-approved HDAC antagonists to treat PAX8-driven epithelial ovarian cancer, and in addition, open up new avenues for prospective basic and clinical investigations. Here, HDAC9 is linked to ovarian carcinoma.